Cytek Biosciences (CTKB) Non Operating Income (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Non Operating Income data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 70.61% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $8.3 million (down 56.39% YoY), and the FY2025 full-year result was $10.5 million, down 28.87% from the prior year.
• Non Operating Income for Q1 2026 stood at $1.1 million, down from $2.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at $10.9 million in Q4 2024 and bottomed at -$946000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $1.7 million (2023), against an average of $2.4 million.
• The widest annual swing landed in 2022, when Non Operating Income sank 325.0%; it then surged 441.18% in 2023.
• A 5-year view of Non Operating Income shows it stood at $4.0 million in 2022, then advanced by 5.41% to $4.2 million in 2023, then soared by 155.44% to $10.9 million in 2024, then slumped by 81.57% to $2.0 million in 2025, then sank by 45.5% to $1.1 million in 2026.
• The last three Non Operating Income figures came in at $1.1 million (Q1 2026), $2.0 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.

Peer Comparison